IKT - Inhibikase Therapeutics, Inc. News

Sectors

IKT

Inhibikase Therapeutics, Inc.

2.17

25 x 2.17

28 x 2.18

bid

ask

0.06

2.47%

12:29 PM

timesize

Ytd	6.10%
1y	12.69%

2.15

day range

2.25

1.33

52 week range

2.36

Open	2.20	Prev Close	2.23	Low	2.15	High	2.25	Mkt Cap	294.43M
Vol	262.05K	Avg Vol	837.64K	EPS	-0.43	P/E	-5.19	Forward P/E	-11.84
Beta	0.94	Short Ratio	0.17	Inst. Own	11.62%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	05-12	50-d Avg	1.85	200-d Avg	1.74	1yr Est	7.00

IKT News

benzinga.com

Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Ma

US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading

benzinga.com

Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facil

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

globenewswire.com

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Faci

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In

globenewswire.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In

globenewswire.com

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activit

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inh

globenewswire.com

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I

globenewswire.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I

globenewswire.com

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I

defenseworld.net

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February

Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increa

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

defenseworld.net

Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Ge

defenseworld.net

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts

Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) has been given a consensus recommendat

defenseworld.net

Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Ge

defenseworld.net

Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

defenseworld.net

Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

defenseworld.net

Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey

Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Fre

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

defenseworld.net

Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

defenseworld.net

Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)

Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Fre

defenseworld.net

Financial Analysis: Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

globenewswire.com

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Fu

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“In

globenewswire.com

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“

globenewswire.com

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA App

globenewswire.com

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activit

BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

Earnings Scheduled For August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q